Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
ISA 2022 – Alnylam takes heart from full Apollo-B data
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
Alnylam’s heart beats stronger
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
